Research Phase. The Parties have agreed upon an initial Research Plan for each of the Fibrosis Application R&D Program, the Muscle Application R&D Program, and the Acetylome Application R&D Program, attached hereto as Exhibit A-0, X-0 xxx X-0, respectively. The applicable Research Plan shall govern the Parties’ respective activities under each R&D Program during the Research Term. Each Research Plan shall include a set of mutually-agreed feasibility studies (“Stage 1 activities”) and a set of novel Biomarker discovery activities (“Stage 2 activities”). The Stage 1 activities and Stage 2 activities under each Research Plan shall collectively make up the research phase (“Research Phase”) of each R&D Program. Each Research Plan will include a detailed plan for the conduct of activities in the first year of the Research Term for the applicable R&D Program. Such first year of activities is anticipated to include Stage 1 activities and, if initiated by GSK during this time, Stage 2 activities, in each case as more fully set forth in the applicable Research Plans. Each Research Plan will include the timelines for such activities associated with the Stage 1 and anticipated activities for Stage 2 activities. Each Research Plan will also include a more general outline of the plan for the conduct of activities in the second and third years of the Research Term for each applicable R&D Program. In the event that the Parties mutually agree to extend the Research Term of an R&D Program, the Parties, via the JRS, will discuss and agree upon a detailed Research Plan for activities to be conducted by each Party during the extended Research Term for such R&D Program.
Research Phase. The Research Phase of the Research Program shall commence, on a Compound by Compound basis, upon the JSC's designation of such Compound as a Hit, and shall extend until the later of (a) the initiation of the Development Phase for such Compound, or (b) such time as the JSC determines, in writing, to discontinue all Research on such Compound and not to advance such Compound to the Development Phase, unless earlier terminated in accordance with Sections 11.4, 11.5, 11.7 or 11.9.1.
Research Phase. During the Research Phase, each party shall use Commercially Reasonable Efforts to perform the activities assigned to it in the Research Plan(s). Neither party shall have any obligation to perform any work beyond that specified in the then current Research Plan(s).
Research Phase. 3.1 From time to time during the Research Phase of this Agreement, Elanco shall propose to Scynexis a Development Plan. Thereafter the parties shall meet and confer to develop a Development Program designed to accomplish the Development Plan. The Development Program, shall, among other things, set forth the budget and allocation of FTEs.
Research Phase. In support of the research to be conducted by Ontogeny in the course of the Research Program, Biogen shall pay Ontogeny, at a rate of [**] per FTE, an amount equal to (i) [**] for each Contract Year during the Research Phase.
Research Phase. 29 4.3.3 Screening Phase Tail....................................................................................... 30 4.3.4
Research Phase a) EVOTEC hereby grants to ROCHE a non-exclusive, royalty free license in the Territory under EVOTEC’s Background Intellectual Property and an exclusive license under the EVOTEC Research Project Intellectual Property and the EVOTEC Produced Compound Intellectual Property and its interest in the Joint Produced Compound Intellectual Property, each with the right to Sublicense within the framework of a Sublicensing agreement, solely and only to the extent necessary to perform its obligations assigned to ROCHE under a particular Research Plan. * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC.
b) ROCHE hereby grants to EVOTEC a non-exclusive, royalty free license in the Territory under ROCHE’s Background Intellectual Property and an exclusive license under the ROCHE Research Project Intellectual Property and the ROCHE Produced Compound Intellectual Property and its interest in the Joint Produced Compound Intellectual Property, each with the right to Sublicense within the framework of a Sublicensing agreement, solely and only to the extent necessary to perform its obligations assigned to EVOTEC under a particular Research Plan.
Research Phase. The following are the Research Phase Deliverables by Nova Biomedical Corporation 4.
Research Phase. Consultant’s work on the Research Phase of the Services shall commence within thirty (30) days of the Effective Date of this Agreement (“Research Commencement Date”), and Consultant shall provide to Client a written report detailing the results of its work for this Phase within ninety (90) days after the Research Commencement Date (“Research Completion Date”). Consultant shall continue to provide the following services as requested by Client during the Term of this Agreement.
1. Identify market retail trade area using political boundaries, drive times and radii and custom boundary geographies;
2. Perform market and retail GAP analysis for trade area (i.e. leakage and surplus);
3. Conduct retail peer market analysis;
4. Tapestry lifestyles – psychographic profile of trade area/market segmentation analysis;
